Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus THEOCLEAR L A 130.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus THEOCLEAR L A 130.
DILOR-400 vs THEOCLEAR L.A.-130
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
130 mg orally every 12 hours; extended-release tablet.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Renal (70% unchanged), hepatic metabolism (30%)
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Category C
Category C
Bronchodilator
Bronchodilator